|Articles|June 10, 2011
Podcast Interview: Chris Garabedian, CEO, AVI BioPharma
In our latest podcast, Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Advertisement
Interview: Chris Garabedian
Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan
2
Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics
3
FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease
4
Educating Patients About GLP-1s: Q&A with Kristen Hartzell, PharmD
5